See the “Disclosure Regarding Non-GAAP Financial Measures” disclosure and the reconciliation tables that accompany this release for a discussion and reconciliation of certain non-GAAP financial measures included in this release. LEHI, Utah–(BUSINESS WIRE)–Owlet, Inc. (“Owlet” or the “Company”) (NYSE:OWLT) today reported financial results for the fourth quarter and fiscal year ended December 31, 2022. Owlet’s … [Read more…]
SAN DIEGO–(BUSINESS WIRE)–#TandemDiabetes–Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced publication of results from the Pediatric Artificial Pancreas (PEDAP) Clinical Trial by the New England Journal of Medicine showing an approximate 3-hour per day increase in time in range* in children ages 2-5 years old using the … [Read more…]
SEATTLE–(BUSINESS WIRE)–Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the Company will release fourth quarter and full year 2022 financial results on Thursday, March 23, 2023, after the close of market. The Company will host a corresponding conference call and … [Read more…]
NEW BRUNSWICK, N.J.–(BUSINESS WIRE)–Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 18th to review first-quarter results. Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call. The question and answer portion of … [Read more…]
Generated Record Full Year Net Sales and Adjusted EBITDA Exceeded Pricing Growth Target Above Inflation in Q4 and Full Year Expects Full Year 2023 Net Sales of $463 to $493 million and adjusted EBITDA of $76 to $82 million JACKSONVILLE, Fla.–(BUSINESS WIRE)–Cadre Holdings, Inc. (NYSE: CDRE) (“Cadre” or “the Company”), a global leader in the … [Read more…]
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT) announced today that three abstracts highlighting the company’s unique, multi-omics capabilities and offerings for biopharmaceutical partners will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19, 2023, at the Orange County Convention Center in Orlando, Florida. “Veracyte’s comprehensive multi-omics … [Read more…]
U.S. Food and Drug Administration (FDA) Grants Fast Track Designation for Belzupacap Sarotalocan (bel-sar) for the Treatment of Choroidal Metastasis, Bel-sar’s Second Ocular Oncology Indication to Receive this Designation Global Phase 3 Trial in Primary Choroidal Melanoma on Track to Begin Dosing in 1H 2023 BOSTON–(BUSINESS WIRE)–Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company … [Read more…]
Announced interim safety and efficacy data for ADI-001 in ongoing Phase 1 study for the potential treatment of relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL); Next data update expected in Q2 2023 Announced preclinical data for differentiated chimeric antigen receptor (CAR) and chimeric adaptor (CAd) programs at The Society for Immunotherapy of Cancer (SITC) 37th … [Read more…]
SAN DIEGO–(BUSINESS WIRE)–Cue Health Inc. (“Cue”) (Nasdaq: HLTH), a healthcare technology company, today reported financial results for the fourth quarter and full-year 2022. Recent and Full-Year 2022 Highlights Reported fourth quarter revenue of $146.8 million, including $92.4 million in deferred revenue related to our agreement with the U.S. Department of Defense. Full-year 2022 revenue was … [Read more…]
LAUSANNE, Switzerland–(BUSINESS WIRE)–ADC Therapeutics SA (NYSE: ADCT) today announced its Annual Report on Form 20-F for the fiscal year ended December 31, 2022, has been filed with the U.S. Securities and Exchange Commission (the “SEC”). ADC Therapeutics’ Annual Report on Form 20-F can be accessed by visiting either the SEC’s website at www.sec.gov or the … [Read more…]
